

F/20 IPP PATENT 10/9/07

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Blumenfeld et al.) Group Art Unit 1655
Appl. No.	:	09/416,384 October 12, 1999) I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C.
For	:	GENES, PROTEINS, AND BIALLELIC MARKERS RELATED TO CENTRAL NERVOUS SYSTEM DISEASE) 20231, on) October 9, 2001 (Date)) Daniel Hart, Reg. No. 40,637
Examiner	:	J. Fredman))

SUPPLEMENTAL RESPONSE TO FINAL OFFICE ACTION

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Please amend the above-identified application as follows:

IN THE CLAIMS:

Please cancel Claims 1-44 and 47-57 without prejudice as being drawn to a non-elected invention.

Remarks

Applicants submit herewith a Request Form for Continued Prosecution Application. Applicants submitted an Amendment on July 31, 2001 which the Examiner did not enter on the assertion that a further search was required to address the limitation regarding "glutamine repeats" in the amended claims.

Applicants respectfully request that the Amendment submitted July 31, 2001 be entered in the present Continued Prosecution Application and that the following additional remarks be considered.